Company intelligence / Profile preview

Dreamhawk Vision Biotech, Inc.

Kaohsiung, Kaohsiung City, Taiwanprnewswire.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Dreamhawk Vision Biotech developed a proprietary antisense oligonucleotide/microRNA therapy platform targeting miR‑328 to treat ophthalmic conditions such as pediatric myopia and dry eye disease. Their lead candidate SHJ002 demonstrated safety in a completed Phase I trial and efficacy in a recently completed Phase II trial for dry eye disease. The company merged with Sunhawk Vision Biotech, which continues the development of these programs.

Therapeutic areas: Ophthalmology
Modalities: Antisense oligonucleotides (ASO)microRNA therapy
Industry: Biotech

Drug pipeline

1 asset

visomitin

Phase 3

Indications: Dry eye disease

Partnerships

International pharmaceutical companies are seeking licensing deals; specific names not disclosed yet.

Beyond the preview

Go deeper on Dreamhawk Vision Biotech, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dreamhawk Vision Biotech, Inc..

Explore the full profile